$2.1 Billion is the total value of Redmile Group, LLC's 68 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RGNX | Buy | REGENXBIO INC | $42,368,731 | +4.6% | 2,574,042 | +27.0% | 2.02% | +29.6% |
| New | RAYZEBIO INC | $41,241,073 | – | 1,857,706 | +100.0% | 1.96% | – | |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $40,877,760 | +93.2% | 774,200 | +97.9% | 1.94% | +139.5% |
| PEN | Buy | PENUMBRA INC | $37,514,435 | -21.5% | 155,076 | +11.6% | 1.78% | -2.7% |
| ANTM | Buy | ELEVANCE HEALTH INC | $37,175,289 | +6.8% | 85,378 | +9.0% | 1.77% | +32.5% |
| SRRK | Buy | SCHOLAR ROCK HLDG CORP | $33,606,061 | +1.2% | 4,733,248 | +7.5% | 1.60% | +25.5% |
| HUM | Buy | HUMANA INC | $29,118,709 | +40.6% | 59,851 | +29.2% | 1.38% | +74.2% |
| CABA | Buy | CABALETTA BIO INC | $27,004,115 | +52.6% | 1,774,252 | +29.5% | 1.28% | +89.2% |
| SYK | Buy | STRYKER CORPORATION | $25,889,053 | -1.2% | 94,738 | +10.3% | 1.23% | +22.5% |
| GRTS | Buy | GRITSTONE BIO INC | $14,635,697 | +9.4% | 8,509,126 | +24.0% | 0.70% | +35.7% |
| New | BIOHAVEN LTD | $13,497,213 | – | 518,924 | +100.0% | 0.64% | – | |
| ADCT | Buy | ADC THERAPEUTICS SA | $12,717,706 | -57.9% | 14,178,045 | +0.9% | 0.60% | -47.8% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $12,669,629 | +95.9% | 465,282 | +118.0% | 0.60% | +143.1% |
| ALLK | Buy | ALLAKOS INC | $9,386,588 | -5.7% | 4,135,061 | +81.1% | 0.45% | +17.0% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $9,295,603 | -4.5% | 6,280,813 | +3.8% | 0.44% | +18.2% |
| HCA | New | HCA HEALTHCARE INC | $6,067,589 | – | 24,667 | +100.0% | 0.29% | – |
| New | MEDAVAIL HOLDINGS INC | $4,194,017 | – | 692,082 | +100.0% | 0.20% | – | |
| New | NEOLEUKIN THERAPEUTICS INC | $2,300,650 | – | 582,443 | +100.0% | 0.11% | – | |
| CUTR | New | CUTERA INC | $2,016,676 | – | 334,996 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.